US Pharma MarketingThe post ESC 2026: Heartflow’s fractional flow reserve tool reduces unnecessary coronary interventions appeared first on Medical Device Network.
ESC 2026: Heartflow’s fractional flow reserve tool reduces unnecessary coronary interventions
The addition of Heartflow’s FFR technology resulted in a 44% reduction in unnecessary ICA at one year, versus 22% with CCTA alone. The addition of Heartflow’s FFR technology resulted in a 44% reduction in unnecessary ICA at one year, versus 22% with CCTA alone. Heartflow’s FFR is an artificial intelligence (AI)-based test applied to standard CT scans to calculate changes in blood pressure and blood flow across any blockages or plaque buildups. Credit: Explode/Shutterstock.com New research has found that adding Heartflow’s fractional flow reserve (FFR) analysis to the diagnostic pathway in patients with stable coronary artery disease (CAD) reduced the…
The addition of Heartflow’s FFR technology resulted in a 44% reduction in unnecessary ICA at one year, versus 22% with CCTA alone.
Source: Medical Device Network